Pharmacotherapy for behavioural manifestations in
frontotemporal dementia: An expert consensus from the European
Reference Network for Rare Neurological Diseases (ERN-RND)

J 2024

Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)

WITTEBROOD, Casper; Marina BOBAN; Annchiara CAGNIN; Sabina CAPELLARI; De Winter FRANCOIS-LAURENT et al.

Základní údaje

Originální název

Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)

Autoři

Vydání

European Journal of Neurology, Hoboken, Wiley, 2024, 1351-5101

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137809

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

drug therapy; expert testimony; frontotemporal dementia; neurobehavioural manifestations; neurodegenerative diseases

Štítky

14110127, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 11. 2024 11:02, Mgr. Tereza Miškechová

Anotace

V originále

Background and PurposeFrontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial-based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.MethodThe study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN-RND).ResultsThe study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self-injury and self-harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.ConclusionsThe survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.

Citovat

WITTEBROOD, Casper; Marina BOBAN; Annchiara CAGNIN; Sabina CAPELLARI; De Winter FRANCOIS-LAURENT; Atbin DJAMSHIDIAN; Manuel Menendez GONZALEZ; Lena E HJERMIND; Lenka KRAJČOVIČOVÁ; Johanna KRUGER; Johannes LEVIN; Kathrin REETZ; Eloy Rodriguez RODRIGUEZ; Jonathan ROHRER; Van Langenhove TIM; Carola REINHARD; Holm GRAESSNER; Robert RUSINA; Dario SARACINO; Marion HOUOT; Harro SEELAR a Rik VANDENBERGHE. Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND). European Journal of Neurology. Hoboken: Wiley, 2024, roč. 31, č. 12, s. 1-11. ISSN 1351-5101. Dostupné z: https://doi.org/10.1111/ene.16446.

@article{2455472,
   author = {Wittebrood, Casper and Boban, Marina and Cagnin, Annchiara and Capellari, Sabina and FrancoisandLaurent, De Winter and Djamshidian, Atbin and Gonzalez, Manuel Menendez and Hjermind, Lena E and Krajčovičová, Lenka and Kruger, Johanna and Levin, Johannes and Reetz, Kathrin and Rodriguez, Eloy Rodriguez and Rohrer, Jonathan and Tim, Van Langenhove and Reinhard, Carola and Graessner, Holm and Rusina, Robert and Saracino, Dario and Houot, Marion and Seelar, Harro and Vandenberghe, Rik},
   article_location = {Hoboken},
   article_number = {12},
   doi = {https://doi.org/10.1111/ene.16446},
   keywords = {drug therapy; expert testimony; frontotemporal dementia; neurobehavioural manifestations; neurodegenerative diseases},
   language = {eng},
   issn = {1351-5101},
   journal = {European Journal of Neurology},
   title = {Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ene.16446},
   volume = {31},
   year = {2024}
}

TY  - JOUR
ID  - 2455472
AU  - Wittebrood, Casper - Boban, Marina - Cagnin, Annchiara - Capellari, Sabina - Francois-Laurent, De Winter - Djamshidian, Atbin - Gonzalez, Manuel Menendez - Hjermind, Lena E - Krajčovičová, Lenka - Kruger, Johanna - Levin, Johannes - Reetz, Kathrin - Rodriguez, Eloy Rodriguez - Rohrer, Jonathan - Tim, Van Langenhove - Reinhard, Carola - Graessner, Holm - Rusina, Robert - Saracino, Dario - Houot, Marion - Seelar, Harro - Vandenberghe, Rik
PY  - 2024
TI  - Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)
JF  - European Journal of Neurology
VL  - 31
IS  - 12
SP  - 1-11
EP  - 1-11
PB  - Wiley
SN  - 13515101
KW  - drug therapy
KW  - expert testimony
KW  - frontotemporal dementia
KW  - neurobehavioural manifestations
KW  - neurodegenerative diseases
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ene.16446
N2  - Background and PurposeFrontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial-based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.MethodThe study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN-RND).ResultsThe study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self-injury and self-harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.ConclusionsThe survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
ER  -

WITTEBROOD, Casper; Marina BOBAN; Annchiara CAGNIN; Sabina CAPELLARI; De Winter FRANCOIS-LAURENT; Atbin DJAMSHIDIAN; Manuel Menendez GONZALEZ; Lena E HJERMIND; Lenka KRAJČOVIČOVÁ; Johanna KRUGER; Johannes LEVIN; Kathrin REETZ; Eloy Rodriguez RODRIGUEZ; Jonathan ROHRER; Van Langenhove TIM; Carola REINHARD; Holm GRAESSNER; Robert RUSINA; Dario SARACINO; Marion HOUOT; Harro SEELAR a Rik VANDENBERGHE. Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND). \textit{European Journal of Neurology}. Hoboken: Wiley, 2024, roč.~31, č.~12, s.~1-11. ISSN~1351-5101. Dostupné z: https://doi.org/10.1111/ene.16446.

Přehled o publikaci